[1] Retatrutide (trials): once-weekly subcutaneous administration, starting low (e.g., 2 mg) and escalating to 4, 8, or 12 mg maintenance, with slower titration used to improve tolerability
This approach mirrors dosing strategies used for other peptides with 1216 hour half-lives, though published 5-amino-1mq pharmacokinetic data in humans remains limited
However, CJC-1295 (especially the DAC version) can cause sustained elevation in IGF-1, whichif mismanagedmay increase the risk of: Insulin resistance Carpal tunnel syndrome Soft tissue growth (in rare, prolonged cases) Pituitary overstimulation That said, these issues are more often associated with excessive dosing or continuous high-frequency use
JH and XF consulted literatures and wrote the manuscript in equal contribution
Nasal spray users often dose morning and early evening, while oral capsule users might prefer morning and bedtime administration
Beyond-use dating principles from the United States Pharmacopeia General Chapter treat preservative-containing solutions as having longer safe in-use windows than preservative-free ones